Back HIV/AIDS HIV/AIDS Topics HIV Treatment

AIDS 2014: Australian Bone Marrow Transplant Patients Show No Detectable HIV

An additional 2 people with long-term HIV infection have no evidence of infectious virus or viral genetic material following bone marrow stem cell transplants to treat leukemia or lymphoma, researchers reported at the 20th International AIDS Conference last month in Melbourne. While these individuals remain on antiretroviral therapy (ART) and therefore cannot be considered functionally cured, they offer further evidence that HIV may be controlled off ART in some cases.

alt

Read more:

AIDS 2014: Novel Techniques Probed in HIV Cure Research

A pair of presentations at the 20th International AIDS Conference in Melbourne described new pathways being explored in the search for either a permanent cure for HIV or for longer-acting drugs. In one study, 2 artificial genes that cause cells to generate antiviral entry inhibitors produced significant inhibition of cellular infection. In the other, a technique that is the exact opposite of the much-explored "kick and kill" strategy (which uses drugs to activate cells latently infected with HIV) used an artificial gene fragment to maintain latently infected cells in a locked-down state that resisted strong immune stimulation.

alt

Read more:

AIDS 2014: Disappointing HIV Cure News Leads to New Questions

The fourth IAS Towards an HIV Cure symposium -- an initiative of the International AIDS Society -- took place July 19-20, prior to the 20th International AIDS Conference in Melbourne.

alt

Read more:

AIDS 2014: Single-tablet HIV Regimens Not Necessarily More Durable

Antiretroviral therapy (ART) regimens consisting of 1 pill taken once-daily -- known as single-tablet regimens -- were not associated with a longer time to treatment discontinuation when compared to some other modern, well-tolerated regimens that involve more pills or twice-daily dosing, according to a study presented at the 20th International AIDS Conference last month in Melbourne.

alt

Read more:

AIDS 2014: What Is Needed to "Step Up the Pace" on HIV Prevention and Treatment?

"Stepping up the pace" -- the theme of AIDS 2014 -- will require a new focus on key populations and geographical concentrations of HIV, as well as intensified efforts to expand coverage of HIV testing and treatment, according to Prof. Salim Abdool Karim, director of CAPRISA, who reviewed the global state of the epidemic and treatment access at the 20th International AIDS Conference held recently in Melbourne.

alt

Read more:

FDA Approves ViiV Single-Tablet Regimen Containing Dolutegravir

ViiV Healthcare announced this week that the U.S. Food and Drug Administration (FDA) has approved its all-in-1 antiretroviral fixed-dose combination pill containing the HIV integrase inhibitor dolutegravir (Tivicay) plus abacavir and lamivudine (the drugs in Epzicom or Kivexa). The new coformulation -- with the brand name Triumeq -- is the first single-tablet regimen that does not contain tenofovir and emtricitabine, making it an option for people with impaired kidney function. HLA-B*5701 genetic screening should be done prior to starting Triumeq to test for abacavir hypersensitivity. [Editor's note: On September 3 ViiV announced that the European Commission has also approved Triumeq.]

alt

Read more:

AIDS 2014 HIV Treatment and Prevention Highlights [VIDEO]

Cal Cohen of the Community Research Initiative of New England sat down with HIVandHepstitis.com to offer his summary of some of the highlights of HIV treatment and prevention research presented at the 20th International AIDS Conference last month in Melbourne, Australia.

alt

Read more: